Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: Evidence from five randomized controlled trials

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10409-10418

  Tang, Na Ping ^a,b   Li, Hua ^b   Qiu, Yun Liang ^b   Zhou, Guo Min ^b   Wang, Yan ^b   Ma, Jing ^b   Chang, Yan ^b   Mei, Qi Bing ^a,c  

^a NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

^b National Shanghai Center for New Drug Safety Evaluation and Research   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adverse events; Colorectal cancer; Efficacy; Metastatic; Panitumumab

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PANITUMUMAB;

COLORECTAL NEOPLASMS; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 84922394039     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2354-6     Document Type: Article

References (39)

1. Siegel R,Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688-94.
3. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366-78.
4. Jemal A, Simard EP, Dorell C, et al.Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105:175-201.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
6. Addeo R, CaragliaM, Cerbone D, et al. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther. 2010;10:499-505.
7. Mitry E, Bouvier AM, Esteve J, Faivre J. Benefit of operative mortality reduction on colorectal cancer survival. Br J Surg. 2002;89:1557-62.
8. Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer. 1993;53:209-14.
9. Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S. EGFRtargeted therapy. Exp Cell Res. 2011;317:2765-71.
10. van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-64.
11. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
12. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-80.
13. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697-705.
14. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28: 4706-13.
15. Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wildtype, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14: 749-59.
16. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-13.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-58.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test.BMJ. 1997;315:629-34.
19. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13:1152-60.
20. Middleton G, Brown S, Lowe C, et al. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in Colorectal cancer therapy trial (PICCOLO). Eur J Cancer. 2013;49:3507-16.
21. Bennett L, Zhao Z, Barber B, et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer. 2011;105:1495-502.
22. OdomD, Barber B, Bennett L, et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapyrefractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011;26:173-81.
23. Peeters M, Siena S, Van Cutsem E, et al. Association of progressionfree survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009;115:1544-54.
24. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007;25: 3238-45.
25. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023-34.
26. Poulin-Costello M, Azoulay L, Van Cutsem E, et al. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Target Oncol. 2013;8:127-36.
27. Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013;19:1902-12.
28. Helbling D, Bodoky G, Gautschi O, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wildtype KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol. 2013;24:718-25.
29. Ibrahim EM, Abouelkhair KM. Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a metaanalysis of randomized clinical trials. Med Oncol. 2011;28:S310-7.
30. Schwartzberg LS, Rivera F, Karthaus M, et al (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plusmFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol [Epub ahead of print]
31. Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer. 2006;94:85-92.
32. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55:657-70.
33. Ouwerkerk J, Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents formetastatic colorectal cancer. Eur J Oncol Nurs. 2010;14:337-49.
34. Vincenzi B, Santini D, Tonini G. Biological interaction between antiepidermal growth factor receptor agent cetuximab and magnesium. Expert Opin Pharmacother. 2008;9:1267-9.
35. Costa A, Tejpar S, Prenen H, Van Cutsem E. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Target Oncol. 2011;6:227-33.
36. Groenestege WM, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117:2260-7.
37. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8:387-94.
38. Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012;23: 1672-9.
39. Kang SP, SaifMW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-identification, prevention, and management. J Support Oncol. 2007;5:451-7.